Written By |
Lenacapavir, has demonstrated 100% efficacy in preventing HIV infections among high-risk individuals
Search
By Our Reporter
As the world prepares to commemorate World AIDS Day on December 1, Uganda's remarkable strides in the fight against HIV/AIDS are in the spotlight. A groundbreaking study has brought promising news: a new preventive drug, Lenacapavir, has demonstrated 100% efficacy in preventing HIV infections among high-risk individuals.
A revolutionary discovery
Lenacapavir, an injectable pre-exposure prophylaxis (PrEP) drug, is administered biannually. Developed by the U.S.-based pharmaceutical company Gilead Sciences, Inc., the drug’s clinical trial, dubbed the PURPOSE 1 study, was conducted across Uganda and South Africa. The trial, which began in 2021, involved 5,300 adolescent girls and young women aged 16-25 deemed at high risk of HIV infection. In Uganda, the research was spearheaded by Makerere University-Johns Hopkins University (MU-JHU) Care Ltd and conducted at multiple sites, including Mityana, Makerere-Kalangala, and AMBSO Masaka.
According to Dr. Flavia Matovu Kiweewa, the lead researcher in Uganda and director of research at MU-JHU Care Ltd, Lenacapavir has emerged as a game-changer. “It is the first time we are seeing zero infections in any study,” she revealed.
Study highlights
The trial targeted high-risk groups, such as women in transactional sex, bar workers, and individuals with multiple sexual partners. These participants were believed to be at imminent risk of infection. Over 26 weeks, none of the 2,134 women who received Lenacapavir contracted HIV. In contrast, 16 new cases occurred in the Truvada group (incidence rate: 1.69 per 100 person-years) and 39 cases in the Descovy group (2.02 per 100 person-years). “Lenacapavir was generally well-tolerated, and no significant safety concerns were observed,” a statement from Gilead Sciences read.
Transformative potential
The discovery has fueled optimism among scientists and health stakeholders. With over 1.5 million people in Uganda and 40 million globally living with HIV, Lenacapavir could revolutionize prevention and treatment. A 2023 UNAIDS report revealed that 1.3 million Ugandans are on antiretroviral therapy, with 95% achieving viral suppression. Dr. Matovu Kiweewa expressed hope that Lenacapavir will be available in Uganda within two years, pending approvals from the World Health Organization (WHO) and the National Drug Authority (NDA). She emphasized that the drug's ease of use—requiring only two injections annually—could significantly enhance adherence and reduce stigma associated with daily oral PrEP.
Challenges ahead
For Lenacapavir to achieve its potential, accessibility and affordability must be prioritized. Gilead has signed royalty-free licensing agreements with six generic manufacturers to facilitate production and distribution in resource-limited settings, including Uganda.
Complementary measures
While Lenacapavir stands out as a groundbreaking innovation, Uganda continues to employ a multifaceted approach to combat HIV. Existing methods include oral PrEP, post-exposure prophylaxis (PEP), the dapivirine vaginal ring, and long-acting injectable cabotegravir (CAB-LA).
Uganda’s widely acclaimed ABC strategy (Abstinence, Be Faithful, Use Condoms) remains integral to prevention efforts. However, Dr. Diana Atwine, Permanent Secretary at the Ministry of Health, warns of rising infections among young people due to declining condom use. She emphasizes the need for robust education campaigns to reinforce prevention.
Global recognition
Uganda’s contribution to the fight against HIV has drawn international praise:
Winnie Byanyima, UNAIDS Executive Director, described Lenacapavir as “a transformative tool” that could help end AIDS as a public health threat by 2030.
Dr. Beatriz Grinsztejn, of the International AIDS Society, commended Ugandan scientists for their role in bringing this innovation to the global stage.
Mitchell Warren, Executive Director of AVAC, lauded Uganda’s efforts and called for equitable and swift delivery of Lenacapavir to those who need it most.
Lenacapavir’s success in clinical trials marks a significant leap in the fight against HIV/AIDS. With concerted efforts to ensure its accessibility, Uganda and the world could move closer to achieving an AIDS-free generation.
Torch Media Africa
